Trial Profile
Denosumab Global Safety Assessment Among Women With Postmenopausal Osteoporosis (PMO), Men With Osteoporosis, and Men and Women Who Receive Prolia With Glucocorticoid Exposure in Multiple Observational Databases
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Bisphosphonates; Bisphosphonates
- Indications Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 01 Nov 2023 Planned End Date changed from 30 Jun 2024 to 31 Jul 2024.
- 01 Nov 2023 Planned primary completion date changed from 30 Jun 2024 to 31 Jul 2024.
- 02 Oct 2023 Planned End Date changed from 29 Sep 2023 to 30 Jun 2024.